NCT03260400 Short-term Implanted Electrodes Following Regenerative Peripheral Nerve Surgery for Improving Prosthetic Limb Control Signals
| NCT ID | NCT03260400 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Amputation Neuroma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2017-12-11 |
| Primary Completion | 2029-05-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2017-12-11 with a primary completion date of 2029-05-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
Eligibility Criteria
Inclusion Criteria: * Participants must be 22 years of age or older. * Participants must have previously undergone an upper limb amputation proximal to the wrist. * For participants without existing RPNI grafts (at the time of enrollment), the residual limb must have sufficient soft tissue quality to support performance of the RPNI operative procedure. Participants sustaining severe crushing or avulsion injuries with substantial superficial and deep scarring may not be appropriate candidates for inclusion in the study. * Participants must be in good health and American Society of Anesthesiologists (ASA) Class I or II (low surgical risk). * Participants must have reliable transportation. * Participants must be able to attend at minimum 2 visits per month while electrodes remain implanted. * Participants must be at least 6 months post-amputation. Exclusion Criteria: * Participants may not be suffering from any severe pain syndrome including complex regional pain syndrome or severe phantom pain. All of these conditions would suggest pathological activity of the nerve and would exclude the participant from participation. * Participants must not be suffering from any untreated mental health disorders and if they have any DSM-5 diagnoses, they must receive approval to participate from their mental health professional. * Participants must not have any medical conditions that, in the opinion of the Principal Investigator, would place them at high risk for a surgical procedure including recent myocardial infarction, cerebrovascular accidents, deep venous thrombosis, pulmonary embolus, uncontrolled diabetes, or end stage renal disease. * Participants must not have used tobacco for at least one month prior to enrollment in the study. * Participants must agree to not use tobacco for the duration of the study. * Participants cannot have sustained bilateral upper extremity amputation. * Participants cannot be pregnant. * Participants must not have other indwelling electronic implants like pacemakers, implantable cardioverter defibrillators, implantable neurostimulators, body worn insulin pumps, or body worn patient monitoring devices. * Participants must not have severe peripheral vascular occlusive disease, venous hypertension of the extremity, or severe lymphedema of the extremity. * Participants must not have an autoimmune condition which is not well controlled by medication. * Participants will not be considered for enrollment in Primary Upper Limb Amputation with RPNI Grafts and Electrode Implantation if their amputation is a traumatic injury or cancer related
Contact & Investigator
Paul Cederna, M.D.
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT03260400 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 75 Years, studying Amputation Neuroma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03260400 currently recruiting?
Yes, NCT03260400 is actively recruiting participants. Contact the research team at cederna@umich.edu for enrollment information.
Where is the NCT03260400 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT03260400 clinical trial?
NCT03260400 is sponsored by University of Michigan. The principal investigator is Paul Cederna, M.D. at University of Michigan. The trial plans to enroll 10 participants.